Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3191-3196

  Huzarski, Tomasz ^a   Byrski, Tomasz ^a   Gronwald, Jacek ^a   Górski, Bohdan ^a   Domagała, Pawel ^a   Cybulski, Cezary ^a   Oszurek, Oleg ^a   Szwiec, Marek ^b   Gugała, Karol ^c   Stawicka, Malgorzata ^d   Morawiec, Zbigniew ^e   Mierzwa, Tomasz ^f   Janiszewska, Hanna ^g   Kilar, Ewa ^c   Marczyk, Elzbieta ^h   Kozak Klonowska, Beata ⁱ   Siołek, Monika ⁱ   Surdyka, Dariusz ^j   Wiśniowski, Rafal ^f   Posmyk, Michal ^k   Sun, Ping ^l   Lubiński, Jan ^a   Narod, Steven A ^l   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Regional Oncology Center   (Poland)

^c Specialist Hospital   (Poland)

^d Oncology Center   (Poland)

^e Department of Oncology   (Poland)

^f Regional Oncology Hospital   (Poland)

^g NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ Regional Oncology Center   (Poland)

^j ST JOHN S CANCER CENTER   (Poland)

^k Center of Oncology   (Poland)

^l WOMEN S COLLEGE HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ADULT; ARTICLE; BRCA1 NEGATIVE BREAST CANCER; BRCA1 POSITIVE BREAST CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARIECTOMY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; VITAL STATISTICS; BREAST NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; REGISTER; TIME; YOUNG ADULT;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; REGISTRIES; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84887094325     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.3571     Document Type: Article

References (20)

1. Peto J, Collins N, Barfoot R, et al: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943-949, 1999
2. Malone KE, Daling JR, Neal C, et al: Frequency of BRCA1/BRCA2 mutations in a populationbased sample of young breast carcinoma cases. Cancer 88:1393-1402, 2000
3. Hartman AR, Kaldate RR, Sailer LM, et al: Prevalence of BRCA1 mutations in an unselected population of triple-negative breast cancer. Cancer 118:2787-2795, 2012
4. Young SR, Pilarski RT, Donenberg T, et al: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86, 2009
5. Lubinski J, Huzarski T, Byrski T, et al: The risk of breast cancer in women with a BRCA1 mutation from Poland and North America. Int J Cancer 131: 229-234, 2012
6. El-Tamer M, Russo D, Troxel A, et al: Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11:157-164, 2004
7. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17, 2004
8. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007
9. Goodwin PJ, Phillips KA, West DW, et al: Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 30:19-26, 2012
10. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
11. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
12. Górski B, Jakubowska A, Huzarski T, et al: A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683-686, 2004
13. Ghadirian P, Robidoux A, Zhang P, et al: The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet 76:421-426, 2009
14. Donenberg T, Lunn J, Curling D, et al: A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat 125:591-596, 2011
15. Thorlacius S, Struewing JP, Hartge P, et al: Population based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352:1337-1339, 1998
16. Warner E, Hill K, Causer P, et al: Prospective study of cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29:1664-1669, 2011
17. Rijnsburger AJ, Obdeijn IM, Kaas R, et al: BRCA1-associated breast cancers behave differently from BRCA2-associated and familial cases: Long-term follow-up of the Dutch MRISC study. J Clin Oncol 28:5265-5273, 2010
18. Passaperuma K, Warner E, Causer PA, et al: Long term results of screening with MRI imaging in women with a BRCA mutation. Br J Cancer 107:24-30, 2012
19. Narod SA, Moody JR, Rosen B, et al: Estimating survival rates after ovarian cancer for women tested for BRCA1 and BRCA2 mutations. Clin Genet 83:232-237, 2013
20. Hopper JL, Jenkins MA, Dowty JG, et al: Using tumour pathology to identify individuals at high genetic risk of breast and colorectal cancers. Pathology 44:89-98, 2012